Abdolrazagh Barzegar
1 
, Masoud Ghadipasha
1 , Nima Rezaei
2,3,4 , Mehdi Forouzesh
1* , Rohollah Valizadeh
5 1 Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
2 Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
3 Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
4 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5 Student Research Committee, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
Implication for health policy/practice/research/medical education:
Bromhexine as a fluidifying agent can be investigated in clinical trials to discover its therapeutic effect on respiratory involvement following COVID-19.
Please cite this paper as: Barzegar A, Ghadipasha M, Rezaei N, Forouzesh M, Valizadeh R. New hope for treatment of respiratory involvement following COVID-19 by bromhexine. J Nephropharmacol. 2021;10(2):e11. DOI: 10.34172/npj.2021.11.